Moderna, Inc. (MRNA)
| Market Cap | 51.85B |
| Revenue (ttm) | 246.71M |
| Net Income (ttm) | -597.70M |
| Shares Out | 394.68M |
| EPS (ttm) | -1.64 |
| PE Ratio | n/a |
| Forward PE | 48.54 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $131.02 |
| Previous Close | $132.98 |
| Change ($) | -1.96 |
| Change (%) | -1.47% |
| Day's Open | 132.47 |
| Day's Range | 128.90 - 135.87 |
| Day's Volume | 9,865,757 |
| 52-Week Range | 18.23 - 169.86 |
The success of Moderna's COVID-19 vaccine could be just the beginning.
Moderna and Pfizer/BioNTech should rake in similar levels of revenue for their vaccines.
The CDC says the two products are not interchangeable, but it added in updated guidance posted Thursday that it's OK to mix the shots in rare circumstances.
Only 0.03% of Moderna shots administered through Jan. 10 resulted in a reported “adverse event.”
Moderna's (MRNA) partner Takeda doses the first participant in a phase I/II study with Moderna's coronavirus vaccine candidate, mRNA-1273 in Japan.
Moderna surged as much as 9% on Thursday on news California has reauthorized a batch of the company's vaccine following an allergy scare. Earlier this week, the state urged a pause on the use...
Developments on both sides of the Pacific Ocean seem to be driving the stock northward.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces first participant dosed in Phase 1/2 study of Moderna COVID-19 Vaccine in Japan led by Takeda.
Inoculation with Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccine in California can resume after the state said it was safe to use the batch of the vaccine that was linked to adverse events in so...
Moderna's Chairman on Biden's COVID-19 Vaccine Promise
Jan.20 -- Moderna Co-Founder and Chairman Noubar Afeyan discusses President Biden's COVID-19 vaccine distribution plan and its chances of success. He also talks about the shortcomings of the i...
Moderna (MRNA) closed the most recent trading day at $125.14, moving +0.1% from the previous trading session.
Covid-19 pharma stocks like NVAX stock and BNTX stock are making headlines as Joe Biden promises to vaccinate 100 million Americans. The post Covid-19 Vaccine Roundup: 5 Pharma Stocks Making t...
Moderna stock has rallied by almost 25% since the beginning of this year, currently trading at levels of around $130 per share. There are a couple of developments that are likely driving the g...
A small number of people at one location in California experienced such effects after being inoculated with mRNA-1273.
These are the healthcare stocks with the best value, fastest growth, and most momentum for February 2021.
We just have to wait to find out if he's right.
The vaccine batch was temporarily paused “out of an extreme abundance of caution” after fewer than 10 people had a severe reaction.
Here's where to invest your money right now.
Two mRNA COVID vaccines aced clinical trials. Now new virus variants are putting them to the test.
The wild volatility in Moderna stock before and after its vaccine approval is coming to an end but its long-term prospects are on the way up. The post Why Moderna Has More Upside Than Its Covi...
Moderna has emerged as a strong competitor after getting authorization for a coronavirus vaccine. But Moderna stock remains on a wild ride.
Both of these biotechs could be big winners in the COVID-19 vaccine market.
Over the past three months MRNA insiders have cashed out of the stock. A restriction on insider sales for certain executives was lifted in late December. This could exacerbate insider sales.
The company wants to see if it can still produce a sufficient response one year after inoculation.
Moderna Inc. (NASDAQ: MRNA) is planning to test the efficacy of COVID-19 vaccine booster shots a year after initial doses of the vaccine have been administered to an individual, CNBC reported ...
Moderna plans to test booster shot for Covid-19 vaccine trial patients
CNBC's Meg Tirrell reports on Moderna's plan to test the longevity of its Covid vaccine.
Moderna is planning to test a booster shot of its Covid-19 vaccine one year after initial vaccination, as duration of protection isn't yet known.
Year 2020 was wild, and left many important threats for 2021. I will summarize the key threats I see, and offer my approach to the markets.
Moderna (MRNA) closed at $124.06 in the latest trading session, marking a -0.39% move from the prior day.
"We are going to live with this virus, we think, forever," he said during a panel discussion at the JPMorgan Healthcare Conference.
Pharmaceutical stocks have many benefits, particularly when their products are in demand. And in 2021, that seems likely to be the case.
In a market rife with speculation, the best speculation may be targeting value. The post 7 Great Speculations for 2021 appeared first on InvestorPlace.
Uber Inc (NYSE: UBER) and Moderna Inc (NASDAQ: MRNA) said they are collaborating on supporting the uptake of COVID-19 vaccines. What Happened: The two companies will initially work on providin...
A coronavirus vaccine authorization, a new partnership, and a bullish revenue forecast have investors excited.
Moderna's vaccine delay is hardly fault of its own. The bigger investment picture becomes visible when you ignore the small setbacks and concentrate on the larger factors - in this case, mRNA-...
COVID-19 Vaccine Production to Ramp Up
Moderna (MRNA) plans to initiate clinical studies on new candidates as potential vaccine for seasonal flu, HIV and the Nipah virus.
Moderna (NASDAQ: MRNA) stock rose by about 4% over the last week to levels of around $113 per share. Here's a quick rundown of the developments for the company over the last week.
Moderna Inc's (NASDAQ: MRNA) coronavirus vaccine candidate mRNA-1273 gained another regulatory approval Tuesday. Separately, the company also announced a high-profile executive appointment.
Uber and pharmaceutical company Moderna have announced a partnership around COVID-19 vaccination, which will include a number of different initiatives. To start, it's only confirmed component ...
Shares of Moderna Inc. were up 0.8% in premarket trading on Tuesday after the company said its COVID-19 vaccine has been authorized in Switzerland. The country has also agreed to purchase 7.5 ...
Uber Technologies Inc. and Moderna Inc. said Tuesday they will collaborate to explore ways to support the uptake of COVID-19 vaccines. The ridesharing and delivery company and the biotech said...
SAN FRANCISCO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Uber Technologies, Inc. (NYSE:...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--José M. Vega, M.D. joins Moderna as Chief Safety Officer.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Swissmedic, the Swiss A...
About MRNA
Moderna, a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company has str... [Read more...]
| Industry Biotechnology | IPO Date Dec 7, 2018 |
| CEO Stephane Bancel | Employees 1,100 |
| Stock Exchange NASDAQ | Ticker Symbol MRNA |
Financial Performance
In 2019, Moderna's revenue was $60.21 million, a decrease of -55.42% compared to the previous year's $135.07 million. Losses were -$514.02 million, 33.6% more than in 2018.
Analyst Forecasts
According to 16 analysts, the average rating for Moderna stock is "Buy." The 12-month stock price forecast is 144.38, which is an increase of 10.20% from the latest price.